Johnson & Johnson is one of the investors that have helped Switzerland’s Biocartis, a biotech company specialising in personalised medicine, raise 30 million euros.

The company says it has successfully closed a Series B equity financing round and attracted two new investors - Debiopharm and Johnson & Johnson Development Corp - thus obtaining a minority stake. The fundraising was underwritten by backers such as Aescap, Biocartis' original lead-investor, Biovest and Advent Venture Partners.

Biocartis develops novel diagnostics technology platforms for “low to highly multiplexed detection of molecular-based biomarkers”. Expalining the decision to invest, Debiopharm’s executive vice president Thierry Mauvernay said his company “recognised some time ago that companion diagnostics would play an increasingly important role in personalised medicine and the cost-effectiveness of healthcare in general”.

Rudi Pauwels, founder and chief executive at Biocartis, believes “the classical isolated elements of diagnostics and pharmaceuticals [will] become more aligned and increasingly part of a much more integrated solution designed to optimise the outcome for the individual patient”. He said the firm plans to actively work together with pharmaceutical, diagnostic and biomarker groups “who can and would like to contribute to the practical realisation of these goals”.